AP2008004447A0 - Orally absorbed pharmaceutical formulation and method of administration - Google Patents

Orally absorbed pharmaceutical formulation and method of administration

Info

Publication number
AP2008004447A0
AP2008004447A0 AP2008004447A AP2008004447A AP2008004447A0 AP 2008004447 A0 AP2008004447 A0 AP 2008004447A0 AP 2008004447 A AP2008004447 A AP 2008004447A AP 2008004447 A AP2008004447 A AP 2008004447A AP 2008004447 A0 AP2008004447 A0 AP 2008004447A0
Authority
AP
ARIPO
Prior art keywords
administration
pharmaceutical formulation
orally absorbed
absorbed pharmaceutical
orally
Prior art date
Application number
AP2008004447A
Other languages
English (en)
Inventor
Muhammed Waseem Tahir Qazi
Anna E Gluskin
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Publication of AP2008004447A0 publication Critical patent/AP2008004447A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AP2008004447A 2005-11-30 2005-11-30 Orally absorbed pharmaceutical formulation and method of administration AP2008004447A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2005/001816 WO2007062494A1 (en) 2005-11-30 2005-11-30 Orally absorbed pharmaceutical formulation and method of administration

Publications (1)

Publication Number Publication Date
AP2008004447A0 true AP2008004447A0 (en) 2008-04-30

Family

ID=38091821

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004447A AP2008004447A0 (en) 2005-11-30 2005-11-30 Orally absorbed pharmaceutical formulation and method of administration

Country Status (15)

Country Link
US (2) US20090214657A1 (xx)
EP (1) EP1954242A4 (xx)
JP (1) JP2009517410A (xx)
CN (1) CN101309668A (xx)
AP (1) AP2008004447A0 (xx)
AR (1) AR057180A1 (xx)
AU (1) AU2005338631B2 (xx)
BR (1) BRPI0520704A2 (xx)
CA (1) CA2630578C (xx)
EA (1) EA200800979A1 (xx)
EC (1) ECSP088403A (xx)
IL (1) IL191531A0 (xx)
NZ (1) NZ567601A (xx)
UY (1) UY29905A1 (xx)
WO (1) WO2007062494A1 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015456A1 (en) * 2007-07-30 2009-02-05 Generex Pharmaceuticals Inc. Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
CN101422431B (zh) * 2007-12-28 2011-03-23 上海医药工业研究院 胰岛素经鼻给药制剂
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
CN100594929C (zh) * 2009-06-24 2010-03-24 薛南荣 口服胰岛素药物及其制备方法
RU2573995C2 (ru) 2009-11-13 2016-01-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, содержащая агонист гпп-1 и метионин
SI2554183T1 (en) 2009-11-13 2018-08-31 Sanofi-Aventis Deutschland Gmbh A pharmaceutical composition comprising the GLP-1 agonist and insulin and methionine
CN102753150A (zh) * 2010-01-12 2012-10-24 诺沃—诺迪斯克有限公司 用于口服给予胰岛素肽的药物组合物
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
SI2611458T1 (sl) 2010-08-30 2017-01-31 Sanofi-Aventis Deutschland Gmbh Uporaba AVE0010 za izdelavo zdravila za zdravljenje sladkorne bolezni tipa 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102228680B (zh) * 2011-06-14 2013-02-27 中国人民解放军第三0二医院 胸腺肽的磷脂/胆盐复合胶束及其制备方法和制剂
WO2013003491A1 (en) * 2011-06-27 2013-01-03 Board Of Regents, The University Of Texas System Toroidal pharmaceutical formulations
PT2750699E (pt) 2011-08-29 2015-11-03 Sanofi Aventis Deutschland Acelerómetro pendular
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
DK2983697T3 (en) 2013-04-03 2019-02-25 Sanofi Sa TREATMENT OF DIABETES MELLITUS WITH LONG-EFFECTIVE FORMULATIONS OF INSULIN
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
EP3006045B3 (en) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
US11166912B2 (en) 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
DK0619730T3 (da) * 1992-10-08 2001-01-29 Supratek Pharma Inc Sammensætninger af antineoplastiske midler inkorporeret i miceller
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
IL122084A (en) * 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6375975B1 (en) * 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6436367B1 (en) * 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6312665B1 (en) * 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
CA2375914A1 (en) * 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same

Also Published As

Publication number Publication date
ECSP088403A (es) 2008-05-30
CN101309668A (zh) 2008-11-19
US20090214657A1 (en) 2009-08-27
EP1954242A1 (en) 2008-08-13
BRPI0520704A2 (pt) 2009-05-19
CA2630578C (en) 2014-04-15
NZ567601A (en) 2010-12-24
JP2009517410A (ja) 2009-04-30
WO2007062494A1 (en) 2007-06-07
US20120171259A1 (en) 2012-07-05
UY29905A1 (es) 2007-05-31
AU2005338631B2 (en) 2011-12-01
IL191531A0 (en) 2008-12-29
AU2005338631A1 (en) 2007-06-07
CA2630578A1 (en) 2007-06-07
AR057180A1 (es) 2007-11-21
EP1954242A4 (en) 2012-08-01
EA200800979A1 (ru) 2008-10-30

Similar Documents

Publication Publication Date Title
AP2008004447A0 (en) Orally absorbed pharmaceutical formulation and method of administration
IL239868A0 (en) Capsular formulation of pirfenidone and pharmaceutically suitable inactive drug substances
IL184735A0 (en) Pharmaceutical formulations and methods of use
TWI349664B (en) Benzimidazole derivatives: preparation and pharmaceutical applications
EP1848541A4 (en) METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS
IL221770A (en) Edamantyl acetamide derivatives, the pharmaceutical composition containing them and its use in the preparation of a drug
IL216931A0 (en) Pharmaceutical formulation that comprisies azelastine and fluticasone and aproduct comprising these as antihistamine and anti - inflammatory agent
IL184758A0 (en) New pharmaceutical compositions useful in the transmucosal administration of drugs
IL177533A (en) Benzimidazole derivatives, their preparation and pharmaceutical compositions comprising them
ZA200901110B (en) Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage from containing same
IL185390A (en) A solid dosage form
IL178067A0 (en) Pharmaceutical dosage forms and compositions
PL1655026T3 (pl) Zawierające diacereinę i meloksikam stałe preparaty farmaceutyczne
GB0404327D0 (en) Pharmaceutical composition and method of using same
ZA200803574B (en) Dietary fiber formulation and method of administration
HK1100352A1 (en) Solid medicament of oral administration and preparation thereof
HK1105872A1 (en) Orally dispersible pharmaceutical composition and process for the preparation thereof
PL1673349T3 (pl) Pochodne benzimidazolu: wytwarzanie i zastosowania farmaceutyczne
EP1855647A4 (en) DELAYED RELEASE PHARMACEUTICAL ORAL DOSAGE FORM AND METHOD OF MANUFACTURING THE SAME
EP1755682A4 (en) SOLID PHARMACEUTICAL PREPARATION
IL191922A0 (en) Pharmaceutical formulations of oxcarbazepine and methods for its preparation
IL189827A0 (en) Pharmaceutical dosage forms and compositions comprising lecoztan
ZA200803791B (en) Orally absorbed pharmaceutical formulation and method of administration
GB0608399D0 (en) Pharmaceutical composition and method of using same
PL380757A1 (pl) Nowe pochodne epirubicyny, ich nowe zastosowanie medyczne oraz farmaceutycznie akceptowalna postać leku